Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Progyny director and Chief Executive Officer Peter Anevski reported an insider transaction dated 10/01/2025. The Form 4 shows 7,977 shares of Progyny common stock were disposed of at a price of $21.52 per share, with the filer retaining beneficial ownership of 539,564 shares following the transaction. The filing explains the sale resulted from shares withheld to cover taxes on vested restricted stock units and notes the remaining reportable shares are held directly by PECO ANEVSKI 2020 SD LLC. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Progyny, Inc. (PGNY) insider Allison Swartz, EVP and General Counsel, reported two transactions on 09/04/2025. 339 shares were withheld to satisfy taxes on vested restricted stock units at a per-share value of $23.54, and 599 shares were sold at $23.53 under a Rule 10b5-1 trading plan entered May 13, 2025. The filings show 78,006 shares beneficially owned after the withholding event and 77,407 shares after the sale, reflecting a net reduction in direct holdings. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Michael E. Sturmer, President and director of Progyny, Inc. (PGNY), reported a sale of 7,977 shares of common stock on 09/04/2025 at a price of $23.54 per share. After the transaction he beneficially owned 296,658 shares. The filing is coded F(1) and explains the shares were withheld to satisfy tax withholding on vested restricted stock units. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Mark S. Livingston, the Chief Financial Officer of Progyny, Inc. (PGNY), reported a routine withholding of shares to cover taxes on vested restricted stock units. On 09/04/2025 he disposed of 479 shares of Progyny common stock at a price of $23.54 per share under transaction code F(1), which the filer explains represents shares withheld to satisfy withholding taxes upon RSU vesting. After the withholding, the reporting person beneficially owned 69,661 shares, held directly. The Form 4 is signed by the reporting person on 09/05/2025.
Form 144 filing for Progyny, Inc. (PGNY) reports a proposed sale of 599 shares of common stock through Fidelity Brokerage Services on 09/04/2025 with an aggregate market value of $14,094.47. The filing shows these shares were acquired the same day as restricted stock vesting and were paid as compensation. The issuer has 85,982,409 shares outstanding. The filing also discloses a prior sale by the same person: 2,398 shares sold on 08/28/2025 for $55,058.08, identified as seller Allison C. Swartz. The form includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Michael E. Sturmer, President and a director of Progyny, Inc. (PGNY), reported a non-discretionary disposition of 448 shares of Progyny common stock on 09/02/2025 at a reported price of $23.67 per share. The filing explains the shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units. After the withholding, Sturmer beneficially owned 304,635 shares, reported in a Form 4 filed by one reporting person and executed via attorney-in-fact on 09/03/2025. The report reflects a routine, tax-related transaction rather than an open-market discretionary sale.
Mark S. Livingston, Chief Financial Officer of Progyny, Inc. (PGNY), reported a Form 4 disclosing a change in his beneficial ownership. The filing shows that on 09/02/2025 2,032 shares of Progyny common stock were disposed (withheld) at a price of $23.67 per share. The filing explains the shares were withheld to satisfy withholding taxes on vested restricted stock units. After the transaction, the reporting person beneficially owns 70,140 shares (direct ownership). The form was signed by Mr. Livingston on 09/03/2025.
Allison Swartz, EVP and General Counsel of Progyny, Inc. (PGNY), reported two transactions on 08/28/2025. She sold 2,398 shares of Common Stock under a Rule 10b5-1 plan at $22.96 per share and had 1,352 shares withheld to cover taxes on vested restricted stock units at an effective price of $23.02 per share. The filings show total beneficial ownership following these transactions of 78,345 shares. The 10b5-1 plan was entered on May 13, 2025, and the Form 4 was signed via attorney-in-fact on 09/02/2025. The report reflects routine disposition and tax-withholding actions by an officer rather than derivative activity.
Progyny, Inc. (PGNY) filed a Form 144 reporting a proposed sale of 2,398 common shares for an aggregate market value of $55,058.08. The shares are to be sold through Fidelity Brokerage Services on the NASDAQ with an approximate sale date of 08/28/2025. The filing shows 85,982,409 shares outstanding for the class listed.
The securities were acquired on 08/28/2025 through restricted stock vesting and the consideration is listed as compensation. The filer reports no securities sold in the past three months and includes the standard representation that the selling person does not possess undisclosed material adverse information.
Progyny director GORDON KEVIN K reported a sale of 2,500 common shares on 08/11/2025 at a price of $22.035. The filing shows 12,501 shares are beneficially owned indirectly by the Kevin Gordon Revocable Declaration of Trust, for which the reporting person serves as trustee.
The form's explanation states 5,147 shares were transferred into that Trust on June 2, 2025 from shares previously reported as directly held. The filing also includes a table entry listing 8,026 shares with a disposition marker but no date or price shown for that line.